FDA批准的具有第一个也是唯一一个tau靶向18F-flortaucipir放射性示踪剂的正电子发射断层扫描(PET)已越来越多地用于描述认知障碍患者的tau病理沉积和分布。这一国际共识的目标是帮助核医学从业者在程序上进行18F-flortaucipirPET成像。
由各国专家组成的多学科工作组讨论并批准了阿尔茨海默病(AD)18F-flortaucipirPET成像的共识,专注于临床情景,病人准备,和管理的活动,以及图像采集,processing,解释,和报告。
这一国际共识和实践指南将有助于促进18F-flortaucipirPET在AD患者中的标准化使用。它将成为临床实践中用于此目的的国际标准。
Positron emission tomography (PET) with the first and only tau targeting radiotracer of 18F-flortaucipir approved by FDA has been increasingly used in depicting tau pathology deposition and distribution in patients with cognitive impairment. The goal of this international
consensus is to help nuclear medicine practitioners procedurally perform 18F-flortaucipir PET imaging.
A multidisciplinary task group formed by experts from various countries discussed and approved the
consensus for 18F-flortaucipir PET imaging in Alzheimer\'s disease (AD), focusing on clinical scenarios, patient preparation, and administered activities, as well as image acquisition, processing, interpretation, and reporting.
This international
consensus and practice
guideline will help to promote the standardized use of 18F-flortaucipir PET in patients with AD. It will become an international standard for this purpose in clinical practice.